Latest publications

Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics. Thyssen JP, Thaçi D, Bieber T, Gooderham M, De Bruin-Weller M, Soong W et al. J Eur Acad Dermatol Venereol 2023 May 29

Component Ana o 3 versus extract for cashew nut allergy: A diagnostic test accuracy study in adults. Kallen EJJ, Bollemeijer JF, Knulst AC, Ehlers AM, Welsing PMJ, Van Ree R et al. Clin Exp Allergy 2023 May 29

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial. Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Thaçi D, De Bruin-Weller M et al. Am J Clin Dermatol 2023 May 22

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Stein Gold L, Thaçi D, Thyssen JP, Gooderham M, Laquer V, Moore A et al. Am J Clin Dermatol 2023 May 17:1-13

Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry. Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E et al. Br J Dermatol 2023 May 13

Limited excretion of dupilumab into breastmilk: A case report. Dekkers C, El Amrani M, Van Luin M, Bakker D, Plusjé L, Van Wijk F et al. J Eur Acad Dermatol Venereol 2023 May 05

Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health. Hermans MM, Pasmans SGMA, De Laat PCJ, Slieker MG, Mendels EJ, De Graaf M et al. JAAD Int 2023 Jun; 11:137-139

The Treat-to-Target Project in Atopic Dermatitis: One Year On. De Bruin-Weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G et al. Acta Derm Venereol 2023 Apr 21; 103:adv5382

Biological tipping point in atopic dermatitis patients treated with different dosing intervals of dupilumab. Dekkers C, Van der Wal MM, El Amrani M, Van Luin M, Bakker DS, De Bruin-Weller M et al. J Invest Dermatol 2023 Mar 28

Developing integrated care pathways for atopic dermatitis-Challenges and unmet needs. Zuberbier T, Beck LA, Bedbrook A, De Bruin-Weller M, Bousquet J, Cork M et al. Clin Transl Allergy 2023 Mar; 13(3):e12236

Accidental allergic reactions to food in adolescents and adults: An overview of the factors involved and implications for prevention. Versluis A, Le TM, Houben GF, Knulst AC, Van Os-Medendorp H et al. Front Allergy 2023; 4:1062049

Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing. Ragamin A, Tupker RA, De Graaf M, Rustemeyer T, Pasmans SGMA, Schappin R et al. Br J Dermatol 2023 Mar 22

Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Achten R, Thijs J, Van der Wal M, Van Luijk C, De Graaf M, Bakker D et al. Allergy 2023 Mar 19

Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series. Achten R, Dekkers C, Bakker D, Van Luijk C, De Graaf M, Van Wijk F et al. Clin Exp Allergy 2023 May; 53(5):586-589

Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis. Achten R, Van der Rijst L, Piena M, Lamers H, De Beer F, De Bruin-Weller M et al. Acta Derm Venereol 2023 Mar 08; 103:adv00881